HCM
HUTCHMED DRCNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$2.78B
P/E Ratio
5.83
EPS
$2.64
Beta
0.45
52W High
$19.50
52W Low
$12.18
50-Day MA
$14.59
200-Day MA
$15.24
Dividend Yield
—
Profit Margin
83.30%
Forward P/E
20.53
PEG Ratio
0.00
About HUTCHMED DRC
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Fundamentals
| Revenue (TTM) | $548.51M |
| Gross Profit (TTM) | $63.87M |
| EBITDA | $-25.85M |
| Operating Margin | -13.20% |
| Return on Equity | 45.30% |
| Return on Assets | -1.62% |
| Revenue/Share (TTM) | $3.19 |
| Book Value | $7.20 |
| Price-to-Book | 2.14 |
| Price-to-Sales (TTM) | 5.07 |
| EV/Revenue | 2.25 |
| EV/EBITDA | 2.40 |
| Quarterly Earnings Growth (YoY) | -98.10% |
| Quarterly Revenue Growth (YoY) | -16.50% |
| Shares Outstanding | $171.90M |
| Float | $508.69M |
| % Insiders | 0.01% |
| % Institutions | 3.06% |
Analyst Ratings
Consensus ($22.85 target)
1
Strong Buy9
Buy2
Hold1
SellData last updated: 4/8/2026